4-(oxazolo[5,4-c]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 英文名称: 4-(oxazolo[5,4-c]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
• 英文别名: 4-Oxazolo[5,4-c]pyridin-2-yl-1,4-diazabicyclo[3.2.2]nonane；2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-[1,3]oxazolo[5,4-c]pyridine
• 化学式: C₁₃H₁₆N₄O
• 分子量: 244.296
• InChiKey: AJMDHGFXFDUETC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  45.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(oxazolo[5,4-c]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 4-(oxazolo[5,4-c]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane hydrochloride
  参考文献：
  名称：

  Pharmaceutical compositions for CNS and other disorders

  摘要：

  公开号：

  EP1219622B1
• 作为产物：
  描述：

  2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶 生成 4-(oxazolo[5,4-c]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
  参考文献：
  名称：

  Pharmaceutical composition for the treatment of CNS and other disorders

  摘要：

  本发明涉及一种治疗哺乳动物中枢神经系统（CNS）和其他疾病的方法，包括人类，在哺乳动物中给予一种穿透中枢神经系统的α7烟碱受体激动剂。同时涉及含有药用可接受载体和穿透中枢神经系统的α7烟碱受体激动剂的药物组合物。

  公开号：

  US20020086871A1

文献信息

• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS
  申请人：O'Neill Thomas Brian

  公开号：US20070099904A1

  公开（公告）日：2007-05-03

  The present invention relates to compounds of formula I The substituent designations are as disclosed. At least one of B Q, D and E is nitrogen. The present invention also provides a method of treating disorders of the Central Nervous System such as schizophrenia and cognitive dysfunction.

  本发明涉及I式化合物。取代基的标识如所披露的那样。B、Q、D和E中至少有一个是氮。本发明还提供了一种治疗中枢神经系统疾病，如精神分裂症和认知功能障碍的方法。
• Therapeutic combination for cognititon enhancement and psychotic disorders
  申请人：Romano Joseph Steve

  公开号：US20050215571A1

  公开（公告）日：2005-09-29

  This invention relates to combinations of an atypical antipsychotic, and a nicotinic receptor agonist or antagonist, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from cognitive impairment disorders or psychotic disorders or conditions.

  本发明涉及一种非典型抗精神病药和一种烟碱受体激动剂或拮抗剂的组合物、含有这种组合物的试剂盒、包含这种组合物的药物组合物以及使用这种组合物治疗患有认知障碍疾病或精神病的患者的方法。
• Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
  申请人：Hurst S. Raymond

  公开号：US20060142349A1

  公开（公告）日：2006-06-29

  The present invention provides methods for identifying compounds useful in modulating α7 nicotinic acetylcholine receptors. The invention also provides compounds that prevent, suppress or inhibit desensitization of an α7 nicotinic acetylcholine receptor, and which resensitize such receptors. Pharmaceutical compositions, and methods of treatment, particularly in regard of neurological diseases are also described.

  本发明提供了鉴定有助于调节α7烟碱乙酰胆碱受体的化合物的方法。本发明还提供了防止、抑制或抑制α7烟碱乙酰胆碱受体脱敏以及使这种受体重新敏化的化合物。本发明还描述了药物组合物和治疗方法，特别是治疗神经系统疾病的方法。
• Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models
  作者：Christopher J. O’Donnell、Bruce N. Rogers、Brian S. Bronk、Dianne K. Bryce、Jotham W. Coe、Karen K. Cook、Allen J. Duplantier、Edelweiss Evrard、Mihaly Hajós、William E. Hoffmann、Raymond S. Hurst、Noha Maklad、Robert J. Mather、Stafford McLean、Frank M. Nedza、Brian T. O’Neill、Langu Peng、Weimin Qian、Melinda M. Rottas、Steven B. Sands、Anne W. Schmidt、Alka V. Shrikhande、Douglas K. Spracklin、Diane F. Wong、Andy Zhang、Lei Zhang

  DOI：10.1021/jm9015075

  日期：2010.2.11

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.
• THERAPEUTIC COMBINATION FOR COGNITION ENHANCEMENT AND PSYCHOTIC DISORDERS
  申请人：Pfizer Products Incorporated

  公开号：EP1699488A2

  公开（公告）日：2006-09-13